437 related articles for article (PubMed ID: 33240476)
1. Emerging treatment options for patients with high-risk myelodysplastic syndrome.
Bewersdorf JP; Carraway H; Prebet T
Ther Adv Hematol; 2020; 11():2040620720955006. PubMed ID: 33240476
[TBL] [Abstract][Full Text] [Related]
2. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
4. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
5. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
Madanat Y; Sekeres MA
Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
8. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
9. Management of myelodysplastic syndromes after failure of response to hypomethylating agents.
Gil-Perez A; Montalban-Bravo G
Ther Adv Hematol; 2019; 10():2040620719847059. PubMed ID: 31156799
[TBL] [Abstract][Full Text] [Related]
10. Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Culos K; Byrne M
Clin Hematol Int; 2019 Jun; 1(2):94-100. PubMed ID: 34595416
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
El-Cheikh J; Bidaoui G; Saleh M; Moukalled N; Abou Dalle I; Bazarbachi A
Clin Hematol Int; 2023 Jun; 5(2-3):143-154. PubMed ID: 37071328
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
Azizi A; Ediriwickrema A; Dutta R; Patel SA; Shomali W; Medeiros B; Iberri D; Gotlib J; Mannis G; Greenberg P; Majeti R; Zhang T
Leuk Lymphoma; 2020 Nov; 61(11):2700-2707. PubMed ID: 32543932
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
14. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Pericole FV; Lazarini M; de Paiva LB; Duarte ADSS; Vieira Ferro KP; Niemann FS; Roversi FM; Olalla Saad ST
Front Oncol; 2019; 9():16. PubMed ID: 30761268
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
17. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.
Shallis RM; Zeidan AM
BMC Hematol; 2018; 18():4. PubMed ID: 29435332
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
Gener-Ricos G; Rodriguez-Sevilla JJ; Urrutia S; Bataller A; Bazinet A; Garcia-Manero G
Leuk Lymphoma; 2024 May; ():1-12. PubMed ID: 38712556
[TBL] [Abstract][Full Text] [Related]
19. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]